DeepIntent, the leading healthcare marketing technology company built to influence patient health and business outcomes, today announced DeepIntent Outcomes, which uses real-world clinical evidence to significantly boost script lift attributed to digital advertising. DeepIntent Outcomes, which is built into its Healthcare Demand-Side Platform (DSP), allows advertisers to measure and automatically optimize live promotions based on script performance from pharmaceutical claims data that is updated regularly.
DeepIntent Outcomes assists healthcare marketers in solving today's common barriers, such as data silos, the use of multiple channels, and delayed reporting. DeepIntent Outcomes enables marketers to use script performance to reduce waste, improve marketing mix in-flight and:
- Plan their strategies focused on insights into patients' and providers' in-market behaviors.
- Enable their media plans for all devices via a single platform;
- Monitor the effects of each campaign in real-time
- Optimize campaign efficiency regularly by automatically modifying creative, reach, frequency, publishers, pricing, and bidding strategy.
DeepIntent Outcomes promotes the ability to measure the combined impact of patient and provider advertisement on script lift as one of the strategic use cases. DeepIntent Outcomes partnered with Publicis Health Media to coordinate and measure ad exposures to patients and caregivers with one of their leading pharmaceutical clients. Through this new platform, their client's script lift has increased by an average of 10-35 %.
Through its collaboration with Komodo Health, DeepIntent Outcomes has access to the industry's most comprehensive, transparent, trusted, and verified healthcare data set, as well as the fastest pharmaceutical data refresh. DeepIntent's healthcare identification graph sees 75% of healthcare providers every day and 86% every month, with a 25% higher overall audience quality for patient campaigns. The combination of these two solutions provides previously unseen capabilities in the pharmaceutical market. DeepIntent was named Best-Buy Side Programmatic Platform by Digiday in 2020, beating out rivals such as Xandr and Verizon Media.
DeepIntent, founded by former Memorial Sloan Kettering data scientists, connects healthcare companies with patients and providers through all devices through proprietary data, media collaborations, and integrations. DeepIntent is seen to increase script lift while enhancing patients' quality of life from across the board, from campaign planning to audience targeting to measuring and maximizing. Its Healthcare Marketing Platform enables marketers at seven of the top ten pharmaceutical companies and major healthcare advertising agencies to have a direct impact on health and business outcomes.